Research programme: antibacterials - Enanta

Drug Profile

Research programme: antibacterials - Enanta

Alternative Names: 6,11 Carbon-bridged ketolides - Enanta; Bicyclolides - Enanta; Bridged bicyclic ketolides - Enanta; Bridged bicyclic macrolides - Enanta; EP-013159; EP-013529-07; EP-014413; EP-014831; EP-014887; EP-014940; EP-014944; EP-015072; EP-015369; EP-13043; EP-13118; EP-13159; EP-13417; EP-13543; EP-14389; EP-14401; EP-14413; EP-14922; Oxime bicyclolide derivatives - Enanta

Latest Information Update: 08 Sep 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Enanta Pharmaceuticals
  • Class Ketolides; Macrolides; Small molecules
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Bacterial infections; Methicillin-resistant Staphylococcus aureus infections; Streptococcal infections; Vancomycin-resistant enterococcal infections

Most Recent Events

  • 03 Sep 2013 Enanta Pharmaceuticals receives additional funding of $US9.2 million from National Institute of Allergy and Infectious Diseases (NIAID) for bicyclolides development in Bacterial infections (including MRSA)
  • 03 Sep 2013 Preclinical trials in drug-resistant Streptococcal infections in USA (IV)
  • 03 Sep 2013 Preclinical trials in drug-resistant Streptococcal infections in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top